Coronavirus Update – WHO Gives A Nod To Human Trials For Vaccines

The efforts to create a vaccine for the deadly coronavirus are in full flow around the world. The WHO has been deploying all its resources towards the same.

Now, the WHO has given two of the vaccine candidates a go-ahead to be used for human trials. Another 60 vaccine candidates are currently in the pre-clinical studies stage as was confirmed by the WHO.

The obvious question is about the candidates that have been given clearance for the next stage. Let’s find out.

Coronavirus Update – French Doctors Make Racist Statement

Coronavirus Update - WHO Gives A Nod To Human Trials For Vaccines


The vaccine candidate jointly developed by CanSino Biological Inc and Beijing Institute of Biotechnology is the first to go ahead. It uses the non-replicating viral vector as the platform which is the same as non-Corona candidates like Ebola. The vaccine developed will be an ‘Adenovirus Type 5’ candidate.

As per sources, adenoviruses are common viruses which cause pneumonia-like symptoms. The expected result is the delivery of potential antigens to stimulate the creation of antibodies. These can expectedly help in fighting the disease.

The other vaccine that has been given clearance is from the US. Creators include a biotech firm Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) combine.

Coronavirus Update - WHO Gives A Nod To Human Trials For Vaccines

Coronavirus Update – Expectant Mothers Choosing Home Birth Over Hospitals

This lipid nanoparticle (LNP) encapsulated mRNA candidate vaccine uses an RNA platform with multiple candidates. In this, the virus’s genetic information is de-coded from the DNA to make proteins. mRNA, or messenger RNA, acts as an intermediary between the genetic information in DNA and the amino acid sequence of proteins, which gives cells command to make proteins that fight the viruses. But such vaccines have not yet been approved for human use, said sources.

Let’s hope that the vaccine creation goes on to finally alleviate the issue.

Leave a comment

Your email address will not be published. Required fields are marked *

Rhythm Bhatia

Rhythm Bhatia

Ask us,
learn more

Share your Feedback/Query with us and our team will get in touch with you within 2 business Days.

tell us a bit more.